Skip to main
HSCS
HSCS logo

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc is demonstrating a positive financial outlook with an upward revision of its FY26 EPS estimate to $(4.17) from a previous $(8.63) due to an increased share count. The anticipated approval of the MyoVista device, alongside the rollout of the MyoVista Insights cloud software platform and expected FDA approval of its first diagnostic algorithm in early 2026, positions the company for a significant market opportunity. These developments underline HeartSciences's commitment to enhancing cardiac screening technology and improving healthcare delivery in various clinical settings.

Bears say

HeartSciences Inc. faces significant risks that could negatively impact its stock outlook, including balance sheet and liquidity challenges, as well as uncertainties surrounding the safety and efficacy of its product candidates during clinical trials. The company's revised revenue estimate for FY2026 has been drastically lowered to $0.1 million from a previous projection of $1.2 million, primarily due to delays related to FDA approvals. Additionally, the firm must navigate competitive pressures, reimbursement challenges, and shifting macroeconomic and healthcare priorities, which further exacerbate the uncertainty surrounding its financial viability and market potential.

HSCS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 2 analysts, HSCS has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.